KEDI Global Longevity Bio Index

U.S. FDA PDUFA target action date for zanzalintinib (December 3, 2026) is a potential first approval for a major new franchise; >10% price impact is estimated, scheduled.

The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.

FDA Prescription Drug User Fee Act (PDUFA) target action date for its seasonal flu vaccine (mRNA-1010) on August 5, 2026; Medium importance as PDUFA dates are major catalysts for biotech stocks, scheduled.

Next quarterly earnings for Q2 2026 are expected to be announced on August 4, 2026; medium impact estimated based on historical volatility during earnings releases, expected.

Sanofi's Q2 2026 earnings results release on July 30, 2026, is expected to have a Medium impact as earnings typically drive 5-10% price volatility scheduled.

Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.

Bristol-Myers Squibb Q2 2026 earnings release on 2026-07-30 scheduled; importance is Low as the announcement of an earnings date typically has a <5% price impact.

IQVIA Holdings is scheduled to announce its second-quarter 2026 financial results before the market opens on or around 2026-07-28, based on past reporting schedules. High importance is estimated as earnings releases typically cause significant price movement, scheduled.

GSK's second-quarter 2026 financial results, estimated to have low impact as a routine announcement, are scheduled.

Q2 2026 earnings release on July 22, 2026. Low importance estimated as no market reaction has occurred yet; event is expected.

Abbott's Q2 2026 earnings release is scheduled for July 16, 2026. Analysts forecast EPS of $1.28. Medium importance estimated as earnings typically drive >5% price movement expected.

Johnson & Johnson Q2 2026 earnings release and conference call, with low impact estimated as a routine event, scheduled.

Leidos will go ex-dividend for its quarterly payout of $0.43 per share on June 15, 2026, scheduled to be paid on June 30, 2026.

Company management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on 2026-06-09. Low importance as conference participation typically has minimal immediate price impact scheduled.

CEO Albert Bourla is scheduled to speak at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026; low impact estimated as conference presentations typically result in minor price fluctuations, scheduled.

New Phase 3 data for the pipeline drug CagriSema to be presented at the American Diabetes Association (ADA) Scientific Sessions on June 7, 2026, with a low price impact scheduled.

European Commission approved AQUIPTA (atogepant) for acute migraine treatment on 2026-06-02. Low importance as label expansions typically result in moderate price movement.

Wolfe Research analysts forecast an 'Outperform' rating and a $260 price target on 2026-06-02 estimated.

Presented new research and data at the 2026 ASCO Annual Meeting for several cancer treatments, including fruquintinib and TAK-928, highlighting potential advancements in personalized cancer care.

Positive results from the EMERALD-3 Phase III trial were presented at the ASCO 2026 meeting on 2026-06-01, showing that Imfinzi and Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in patients with unresectable liver cancer; high market impact (>=10%) expected due to significant clinical efficacy.

Moderna and Merck to present positive 5-year follow-up data from the Phase 2b study of their personalized cancer vaccine, intismeran autogene, at the 2026 ASCO Annual Meeting on June 1, 2026, showing a 49% reduction in risk; High importance due to the significant 49% reduction in recurrence risk, likely causing ≥10% price impact, scheduled.

The European Commission granted marketing authorization for IMDYLLTRA® (tarlatamab) on 2026-06-01 for the treatment of ES-SCLC; expected to have a medium market impact of approximately 5% due to expanded market access.

Biogen and partner UCB announced that their Phase 3 PHOENYCS GO clinical trial for dapirolizumab pegol met its primary endpoint; a 5-10% price impact is estimated as Phase 3 success in a major indication is a significant catalyst, scheduled.

New data for Cosentyx, ianalumab, and Scemblix to be presented at the EULAR and ASCO 2026 congresses on 2026-06-01, highlighting positive results in immunology and oncology scheduled. Medium importance is estimated as clinical data for key drugs typically drives a 5% market reaction scheduled.

The European Commission approved Opdivo (nivolumab) in combination with AVD on 2026-06-01 for the treatment of Hodgkin Lymphoma; importance is Low as single-indication approvals typically result in a 1-3% price impact.

The U.S. FDA accepted a supplemental New Drug Application for Camzyos on 2026-06-01, granting Priority Review; importance is Low as application acceptance is a procedural milestone with minor price impact.

Announced the filing of a new shelf registration in Japan for up to JPY 240 billion to issue shares related to its Long Term Incentive Plan (LTIP), with an estimated dilution of around 1.1% for FY2026.

Announced positive Phase 3 results for cancer drug Retevmo in early-stage RET fusion-positive non-small cell lung cancer, showing an 83% reduction in the risk of disease recurrence or death; high impact due to breakthrough clinical data expected

Johnson & Johnson announced positive results from the Phase 1b/2 OrigAMI-4 clinical trial for amivantamab in treating advanced head and neck cancer, showing a 42% overall response rate in heavily pretreated patients.

Law firms scheduled to issue reminders on May 31, 2026, regarding the June 8, 2026 class-action lawsuit deadline concerning business metrics; this is estimated to cause a 1-5% price decline expected.

Announced results from a subgroup analysis of the Phase 3 CABINET pivotal trial at ASCO 2026, showing CABOMETYX® (cabozantinib) significantly improved progression-free survival in patients with advanced neuroendocrine tumors (NET).

Presented positive Phase 3 TALAPRO-3 trial results for the Talzenna and Xtandi combination, showing a 52% reduction in risk of radiographic progression or death in men with a specific type of metastatic prostate cancer.

The US FDA approved Imfinzi in combination with BCG therapy for the treatment of adult patients with a specific type of high-risk, non-muscle-invasive bladder cancer on 2026-05-29; medium market impact (>=5%) expected due to indication expansion.

Biogen and Denali announced the discontinuation of BIIB122 for Parkinson's disease on May 29, 2026; a 5-10% price impact is estimated due to the loss of a mid-stage candidate, scheduled.

European Commission authorized expanded label for VENCLYXTO (venetoclax) for untreated CLL on 2026-05-29. Low importance as label expansions typically result in moderate price movement.

The CARES Phase III clinical program for anselamimab did not meet its primary endpoint on 2026-05-29, but a prespecified subgroup analysis showed a clinically meaningful benefit for patients with kappa light chain amyloidosis; low market impact (>=1%) expected due to mixed clinical results.

The ex-dividend date for a quarterly cash dividend of $0.01 per share, payable on July 1, 2026.

Announced positive Phase 3 SUCCESSOR-2 trial results for mezigdomide on 2026-05-29, showing a 52% reduction in disease progression risk; importance is Low as clinical trial results usually impact price by 1-4%.

The FDA granted Breakthrough Therapy Designation for the investigational KRAS G12C inhibitor calderasib (MK-1084) on May 29, 2026.

Scheduled to announce a collaboration with Diakonos Oncology for a Phase I/II clinical trial on 2026-05-29; Low importance due to expected >1% price impact from clinical collaboration scheduled.

Announced seven-year follow-up results from the Phase 3 CROWN trial for LORBRENA, showing an 81% reduction in the risk of disease progression or death in a type of advanced lung cancer.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization on May 29, 2026, for rilzabrutinib (Wayrilz) to treat adults with immune thrombocytopenia (ITP).

U.S. FDA approved Decnupaz (pivekimab sunirine-pvzy), an ADC acquired via ImmunoGen, for adult BPDCN on 2026-05-28. High importance is estimated as the first ADC for this rare blood cancer, likely driving significant market impact.

Partner GSK announced positive pivotal Phase 3 data for bepirovirsen in chronic hepatitis B, showing a statistically significant 19% functional cure rate. The results were published in the New England Journal of Medicine, and first regulatory decisions are anticipated in Q3 2026.

CVS Caremark announced it will add Lilly's obesity drugs Foundayo and Zepbound to its preferred formularies, significantly expanding patient access; high impact due to increased market share expected

The US FDA extended the decision date for the SERENA-6 regulatory filing of camizestrant to 2026-05-28 to enable the review of additional data; low market impact (>=1%) expected due to regulatory delay.

The FDA approved a label expansion for TREMFYA® (guselkumab) for the treatment of adults with active psoriatic arthritis, making it the only IL-23 inhibitor with an indication for inhibiting the progression of structural damage.

General Counsel Stephen P. Ewald scheduled to sell 16,349 shares at $450.00 per share on May 28, 2026; this insider selling is estimated to cause a 1-5% price decline expected.

An FDA advisory committee (VRBPAC) to vote on recommending a monovalent XFG vaccine for the 2026-2027 COVID-19 season on May 28, 2026, a strain for which Moderna has presented positive immunogenicity data; Low importance as advisory committee votes are preliminary and usually result in 1-5% impact, scheduled.

Announced on 2026-05-28 that its antibody maftivimab was recommended by the WHO for clinical trial evaluation; expected to have a low impact as an early-stage development milestone.

The U.S. FDA granted Priority Review on May 28, 2026, to the New Drug Application for venglustat for the treatment of type 3 Gaucher disease, with a target action date of November 25, 2026.